364 related articles for article (PubMed ID: 23359111)
1. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ
Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111
[TBL] [Abstract][Full Text] [Related]
2. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
3. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
Zhang B; Jiao J; Liu Y; Guo LX; Zhou B; Li GQ; Yao ZJ; Zhou GB
PLoS One; 2012; 7(11):e48748. PubMed ID: 23185274
[TBL] [Abstract][Full Text] [Related]
7. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
8. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
[TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
10. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
12. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
14. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
15. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
16. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
17. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
19. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
La Monica S; Caffarra C; Saccani F; Galvani E; Galetti M; Fumarola C; Bonelli M; Cavazzoni A; Cretella D; Sirangelo R; Gatti R; Tiseo M; Ardizzoni A; Giovannetti E; Petronini PG; Alfieri RR
PLoS One; 2013; 8(10):e78656. PubMed ID: 24167634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]